GLP-1 agonists: US sees 700% increase in non-diabetic patients starting treatment in 12 years

The number of patients without diabetes but with overweight or obesity who started glucagon like peptide-1 receptor agonist (GLP-1RA) treatment in the US has risen from around 21 000 in 2019 to over 174 000 between 2019 and 2023—more than 700%—a study has found.1Researchers from the University of Pennsylvania and Cedars-Sinai Medical Center, Los Angeles, used TriNetX, a federated health research network with 45 million de-identified patient records, to assess the annual trends in new GLP-1RA prescriptions in the US between 2011 and 2023.They found that over that 12 year period, 871 854 people were recorded as being prescribed a GLP-1RA. Users were disproportionately female (59.6%) and just under two thirds (63.5%, 553 310 people) had a body mass index (BMI) of 30 kg/m2 or greater, while 13.7% (119 602) had a BMI of 25 to 29.9, and 4.2% (36 919) had a BMI of 24.9 or under. Notably, an…
Read Original Article: GLP-1 agonists: US sees 700% increase in non-diabetic patients starting treatment in 12 years »